Haas F - Search Results

1

[Polyposis of the nasal sinuses. Epidemiology and clinical aspects of 350 cases. Treatment and results with a follow-up over 5 years on 93 cases].

Braun JJ, Haas F, Conraux C. Braun JJ, et al. Among authors: haas f. Ann Otolaryngol Chir Cervicofac. 1992;109(4):189-99. Ann Otolaryngol Chir Cervicofac. 1992. PMID: 1485748 Review. French.

2

[Skull vault bone graft in augmentation septorhinoplasty].

Mayot D, Perrin C, Haas F, Brunet A. Mayot D, et al. Among authors: haas f. Ann Otolaryngol Chir Cervicofac. 1990;107(8):571-6. Ann Otolaryngol Chir Cervicofac. 1990. PMID: 2085262 Review. French.

3

Immunohistological characteristics of nasal polyps. A comparison with healthy mucosa and chronic sinusitis.

Jankowski R, Béné MC, Moneret-Vautrin AD, Haas F, Faure G, Simon C, Wayoff M. Jankowski R, et al. Among authors: haas f. Rhinol Suppl. 1989;8:51-8. Rhinol Suppl. 1989. PMID: 2672277

4

The influence of coronary angiography and angioplasty on parameters of hemostasis and fibrinolysis.

Six AJ, Tjon RM, Buys EM, Haas F, Hollander-van Zalk A, Haverkate F. Six AJ, et al. Among authors: haas f. Thromb Haemost. 1990 Aug 13;64(1):113-6. Thromb Haemost. 1990. PMID: 2148844

5

The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol: consequences for the assessment of the dose.

van Geest-Daalderop JH, Hutten BA, Péquériaux NC, Haas FJ, Levi M, Sturk A. van Geest-Daalderop JH, et al. Thromb Haemost. 2007 Oct;98(4):738-46. doi: 10.1160/th06-11-0645. Thromb Haemost. 2007. PMID: 17938796

6

Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism.

Schutgens RE, Esseboom EU, Snijder RJ, Haas FJ, Verzijlbergen F, Nieuwenhuis HK, Lisman T, Biesma DH. Schutgens RE, et al. Among authors: haas fj. J Lab Clin Med. 2004 Aug;144(2):100-7. doi: 10.1016/j.lab.2004.04.006. J Lab Clin Med. 2004. PMID: 15322504 Clinical Trial.

7

Pretreatment with oral anticoagulants decreases platelet activation in patients before and after percutaneous coronary intervention.

ten Berg JM, Gerritsen WB, Haas FJ, Kelder JC, Verheugt FW, Thijs Plokker HW. ten Berg JM, et al. Thromb Haemost. 2002 Dec;88(6):924-30. Thromb Haemost. 2002. PMID: 12529740 Clinical Trial.

8

High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention.

ten Berg JM, Gerritsen WB, Haas FJ, Kelder HC, Verheugt FW, Plokker HW. ten Berg JM, et al. Thromb Res. 2002 Mar 1;105(5):385-90. doi: 10.1016/s0049-3848(02)00040-3. Thromb Res. 2002. PMID: 12062539 Clinical Trial.

9

Diagnostic possibilities of specific fibrin(ogen) degradation products in relation to venous thromboembolism.

Haas FJ, Schutgens RE, Biesma DH, Laterveer RH, Kluft C. Haas FJ, et al. Blood Coagul Fibrinolysis. 2013 Apr;24(3):297-304. doi: 10.1097/MBC.0b013e32835bdcbd. Blood Coagul Fibrinolysis. 2013. PMID: 23187785

10

Patients with deep venous thrombosis and thrombophilia risk factors have a specific prolongation of the lag time in a chromogenic thrombin generation assay.

Haas FJ, Kluft C, Biesma DH, Schutgens RE. Haas FJ, et al. Blood Coagul Fibrinolysis. 2011 Sep;22(6):506-11. doi: 10.1097/MBC.0b013e328347404d. Blood Coagul Fibrinolysis. 2011. PMID: 21537160

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results